Drug
Wsd0922 FU
Wsd0922 FU: highest development phase Phase 2, developed by Wayshine Biopharm, Inc.. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Wayshine Biopharm, Inc.
Trials
| Drug | Phase | Indication |
|---|---|---|
| WSD0922-FU Tablets, Dose level A NCT06868485 | Phase 2 | Non Small Cell Lung Cancer |
Latest
No recent events.
Follow Wsd0922 FU on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.